# Neupulse

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/neupulse

- Industry: Medical Devices & Equipment
- Headquarters: Nottingham, UK
- Website: www.neupulse.co.uk
- Total disclosed funding: $3.8M
- Latest round: Seed (Jul 23, 2024)
- Investors on record: 3

## About

Based in Nottingham, UK, and founded in 2021, Neurotherapeutics Ltd., trading under the name Neupulse, operates as a medical device manufacturer. In February 2026, Neupulse raised GBP 3 million in venture funding led by Eos, with participation from Mercia Ventures. 

The company specializes is dedicated to enhancing the lives of individuals with Tourette Syndrome (TS) through non-drug treatment. Neupulse’s solutions include wearable wrist devices designed to deliver gentle stimulation to the median nerve, offering individuals control over their tics and symptom management, with the press of a button. This device has shown results in reducing tic frequency and severity in clinical trials. Additionally, Neupulse is developing the Neutrack mobile app, which monitors TS symptoms over time and identifies external factors that may influence symptom severity. 

The company plans to use the February 2026 funding to support sales growth, product development, regulatory progress, and early commercialization.

## Funding rounds

- Seed, Jul 23, 2024, $0.7M — Foresight Group, Mercia Asset Management
- Seed, Feb 8, 2024, $3.2M — Eos

## Investors

- Eos — Seed
- Foresight Group (https://capitalatlas.ai/funds/foresight-group) — Seed
- Mercia Asset Management (https://capitalatlas.ai/funds/mercia-asset-management) — Seed